Literature DB >> 11405289

Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.

S Cisternino1, C Rousselle, C Dagenais, J M Scherrmann.   

Abstract

PURPOSE: This study was conducted to assess the influence of P-glycoprotein (P-gp) on brain uptake of multidrug resistance sensitive drugs using an in situ brain perfusion technique in P-gp-deficient (mdr1a[-/-]) and wild-type mice.
METHODS: The blood-brain transport of radiolabeled vinblastine, vincristine, doxorubicin, colchicine, and morphine was evaluated in mdr1a(-/-) and wild-type CF-1 mice with the in situ brain perfusion technique. Brain uptake of drugs after intravenous pretreatment with P-gp reversal agents, (PSC 833, GF 120918, or (+/-)-verapamil), or vehicle also was studied in wild-type mice. In all experiments, cerebral vascular volume was determined by co-perfusion of sucrose.
RESULTS: Cerebral vascular volume was preserved during perfusion, indicating maintenance of blood-brain barrier integrity in both types of mice within the concentration range of substrates in the perfusate. The apparent brain transport of colchicine. vinblastine, doxorubicin, and morphine was increased 3.0, 2.7, 1.5, and 1.4-fold, respectively, in mdr1a(-/-) mice compared with the wild-type: the brain uptake of vincristine was not affected by P-gp. Preadministration of PSC 833 or GF 120918 in wild-type mice led to a -3-fold increase in the brain transport of colchicine and vinblastine, but no effect was observed for the other compounds. Intravenous verapamil enhanced colchicine brain transport (1.8-fold), but failed to increase the brain uptake of vinblastine and morphine.
CONCLUSION: The in situ brain perfusion technique appears to be a sensitive and powerful tool for medium throughput screening of the brain uptake of multidrug resistance sensitive drugs. The effect of P-gp is characterized more efficiently with mdr1a(-/-) mice than by using modulators of P-gp in wild-type mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405289     DOI: 10.1023/a:1011080418027

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

Review 1.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Authors:  S V Ambudkar; S Dey; C A Hrycyna; M Ramachandra; I Pastan; M M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

2.  Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.

Authors:  W D Stein; C Cardarelli; I Pastan; M M Gottesman
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

Review 3.  [The blood-brain barrier. I. Morphologic data].

Authors:  J J Hauw; J M Lefauconnier
Journal:  Rev Neurol (Paris)       Date:  1983       Impact factor: 2.607

4.  Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

Authors:  J van Asperen; O van Tellingen; A H Schinkel; J H Beijnen
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

5.  New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

Authors:  C Rousselle; P Clair; J M Lefauconnier; M Kaczorek; J M Scherrmann; J Temsamani
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

6.  Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Biochim Biophys Acta       Date:  2000-08-31

7.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

8.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine.

Authors:  N Drion; M Lemaire; J M Lefauconnier; J M Scherrmann
Journal:  J Neurochem       Date:  1996-10       Impact factor: 5.372

10.  Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

Authors:  J van Asperen; O van Tellingen; F Tijssen; A H Schinkel; J H Beijnen
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more
  20 in total

Review 1.  Additional transporter characterization may lead to new pharmaceutical opportunities.

Authors:  O S Gudmundsson
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Transport screening of drug cocktails through an in vitro blood-brain barrier: is it a good strategy for increasing the throughput of the discovery pipeline?

Authors:  V Berezowski; C Landry; S Lundquist; L Dehouck; R Cecchelli; M P Dehouck; L Fenart
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

Review 3.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 4.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma.

Authors:  Martina da Ros; Anna Lisa Iorio; Dario Consolante; Francesco Cardile; Monica Muratori; Ornella Fantappiè; Maurizio Lucchesi; Milena Guidi; Claudio Pisano; Iacopo Sardi
Journal:  Am J Cancer Res       Date:  2016-02-15       Impact factor: 6.166

Review 6.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

7.  Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.

Authors:  C Dagenais; J Zong; J Ducharme; G M Pollack
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

8.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.

Authors:  Diane Palmieri; Paul R Lockman; Fancy C Thomas; Emily Hua; Jeanne Herring; Elizabeth Hargrave; Matthew Johnson; Natasha Flores; Yongzhen Qian; Eleazar Vega-Valle; Kunal S Taskar; Vinay Rudraraju; Rajendar K Mittapalli; Julie A Gaasch; Kaci A Bohn; Helen R Thorsheim; David J Liewehr; Sean Davis; John F Reilly; Robert Walker; Julie L Bronder; Lionel Feigenbaum; Seth M Steinberg; Kevin Camphausen; Paul S Meltzer; Victoria M Richon; Quentin R Smith; Patricia S Steeg
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

10.  Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.

Authors:  Ramakrishna Samala; Helen R Thorsheim; Satyanarayana Goda; Kunal Taskar; Brunilde Gril; Patricia S Steeg; Quentin R Smith
Journal:  Pharm Res       Date:  2016-08-19       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.